Abstract
The increased cardiovascular risk has been implicated in both HIV infection and antirretroviral therapy. The endothelial dysfunction triggered by the infection and the metabolic abnormalities associated with therapy predispose to premature atherosclerosis. The recognition of the increased cardiovascular risk in these patients will allow more appropriate prevention strategies, as well as therapy optimization with lipid-lowering agents and antirretroviral therapy modification.
| Translated title of the contribution | Cardiovascular risk in HIV infected patients |
|---|---|
| Original language | Portuguese |
| Pages (from-to) | 669-76 |
| Number of pages | 7 |
| Journal | Acta Médica Portuguesa |
| Volume | 23 |
| Issue number | 4 |
| Publication status | Published - Jul 2010 |
Keywords
- :IMMUNODEFICIENCY-VIRUS-INFECTION
- PROTEASE INHIBITOR THERAPY
- TREATMENT PANEL-III
- ANTIRETROVIRAL THERAPY
- METABOLIC SYNDROME
- INSULIN-RESISTANCE
- DYSLIPIDEMIA
- MANAGEMENT
- EFAVIRENZ
- ADULTS
